2021
Safety and efficacy outcomes of the Pioneer Plus catheter in endovascular revascularization of lower extremity chronic total occlusions
Sheikh AB, Llanos-Chea F, Jelani QU, Anantha-Narayanan M, Attaran R, Schneider M, Ionescu C, Regan C, Nagpal S, Smolderen KG, Mena-Hurtado C. Safety and efficacy outcomes of the Pioneer Plus catheter in endovascular revascularization of lower extremity chronic total occlusions. Journal Of Vascular Surgery 2021, 74: 746-755. PMID: 33592298, DOI: 10.1016/j.jvs.2021.01.045.Peer-Reviewed Original ResearchConceptsMajor adverse limb eventsAdverse limb eventsDevice-related complicationsProcedure-related complicationsProcedure-related outcomesProcedural successEfficacy outcomesPseudoaneurysm formationSafety outcomesLimb eventsLower extremity chronic total occlusionMajor adverse cardiovascular eventsChronic total occlusion interventionAccess site hematomaAcute arterial thrombosisAcute limb ischemiaAdverse cardiovascular eventsProvider-level factorsArteriovenous fistula formationHigh-volume centersChronic total occlusionMajor bleedingPreprocedural symptomsCardiovascular eventsCatheter use
2020
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies
Bikdeli B, Talasaz AH, Rashidi F, Sharif-Kashani B, Farrokhpour M, Bakhshandeh H, Sezavar H, Dabbagh A, Beigmohammadi MT, Payandemehr P, Yadollahzadeh M, Riahi T, Khalili H, Jamalkhani S, Rezaeifar P, Abedini A, Lookzadeh S, Shahmirzaei S, Tahamtan O, Matin S, Amin A, Parhizgar SE, Jimenez D, Gupta A, Madhavan MV, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Mohebbi B, Piazza G, Kirtane AJ, Lip GYH, Krumholz HM, Goldhaber SZ, Sadeghipour P. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thrombosis Research 2020, 196: 382-394. PMID: 32992075, PMCID: PMC7513771, DOI: 10.1016/j.thromres.2020.09.027.Peer-Reviewed Original ResearchConceptsStandard-dose prophylactic anticoagulationKey safety endpointIll patientsProphylactic anticoagulationVenous thromboembolismMajor bleedingSafety endpointCOVID-19Bleeding Academic Research Consortium definitionAcademic Research Consortium definitionsTimes upper normal limitAcute arterial thrombosisExuberant immune responseMacrovascular thrombotic eventsPrespecified secondary analysisCritically ill patientsKey secondary endpointVentilator-free daysExtracorporeal membrane oxygenationUpper normal limitNon-inferiority marginReverse transcription-polymerase chain reactionCoronavirus disease 2019Transcription-polymerase chain reactionAtorvastatin 20
2005
Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: Importance of synergistic factors
Page C, Rubin LE, Gusberg RJ, Dardik A. Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: Importance of synergistic factors. Journal Of Vascular Surgery 2005, 42: 1014-1018. PMID: 16275464, DOI: 10.1016/j.jvs.2005.06.019.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAcute DiseaseAngiographyFactor VFactor V DeficiencyFibrinolytic AgentsFollow-Up StudiesHeparinHeterozygoteHumansHyperhomocysteinemiaInjections, Intra-ArterialMaleMiddle AgedMutationPeripheral Vascular DiseasesPopliteal ArteryThromboembolismThrombolytic TherapyTissue Plasminogen ActivatorConceptsPeripheral arterial diseaseArterial diseaseArterial thrombosisPre-existing peripheral arterial diseaseAcute popliteal artery thrombosisAcute arterial thrombosisPopliteal artery thrombosisIntra-arterial thrombolysisRisk factor modificationDeep venous thrombosisLong-term treatmentFactor V LeidenArtery thrombosisAcute thrombosisVenous thrombosisHomocysteine levelsFactor modificationV LeidenNormal limitsThrombosisHyperhomocysteinemiaFolic acidDiseaseDisordersAnticoagulation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply